PARP inhibitors in prostate cancers, is it time for combinations?
Sign Up to like & getrecommendations! Published in 2024 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359241242959
Abstract: Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval… read more here.
Keywords: oncology; time combinations; inhibitors prostate; prostate cancers ... See more keywords